Source: BioSpace
Area: News
The European Commission has granted marketing authorisation for aflibercept (EyleaT) injection, for the treatment of neovascular (wet) age-related macular degeneration (AMD).
According to the Summary of Product Characteristics, treatment is initiated with one 2 milligram injection per month for three consecutive months, followed by one injection every two months with no requirement for monitoring by the physician between injections. After the first twelve months of treatment, the treatment interval may be extended based on visual and anatomic outcomes.
In the United States, aflibercept is (Read more...)
Uncategorized